 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the companys multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy OHE. OHE is a con 